- EPS of $0.15 beat analyst estimates by 87.5%
- Quarterly sales of $28.400 million missed consensus by 4.27%
- Revenue grew 7.85% YoY from $26.334 million
- EPS increased 66.67% YoY from $0.09
*this image is generated using AI for illustrative purposes only.
Sanara MedTech reported third-quarter earnings per share of $0.15, exceeding the analyst consensus estimate of $0.08 by 87.5%. This represents a 66.67% increase from the $0.09 per share recorded in the same period last year.
Despite the earnings beat, quarterly sales clocked in at $28.400 million, falling short of the consensus estimate of $29.667 million by 4.27%. However, revenue demonstrated year-over-year growth, rising 7.85% from $26.334 million in the corresponding quarter of the previous year.
What the Numbers Show
The divergence between the significant earnings beat and the slight revenue miss suggests improved profitability or cost efficiency relative to top-line growth. While sales grew modestly by 7.85% YoY, the EPS expansion of 66.67% indicates that profit generation outpaced revenue accumulation significantly during this period.
Quarterly Performance Snapshot
Historical Stock Returns for Sanara MedTech
How will Sanara MedTech's improved cost efficiency impact its gross margin targets for the upcoming fiscal year?
What specific operational changes or product mix shifts drove the 66.67% EPS growth despite the revenue shortfall?
Is the slight revenue miss indicative of broader demand softness in the wound care market or specific to Sanara MedTech's distribution channels?